Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02027961
Title Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors MedImmune LLC
Indications

melanoma

Therapies

Dabrafenib + Durvalumab + Trametinib

Durvalumab + Trametinib

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST